Davidson R N, Di Martino L, Gradoni L, Giacchino R, Russo R, Gaeta G B, Pempinello R, Scott S, Raimondi F, Cascio A
St Mary's Hospital Medical School, Dept of Infectious and Tropical Diseases, Lister Unit, Northwick Park Hospital, Harrow, UK.
Q J Med. 1994 Feb;87(2):75-81.
Thirty-one patients with visceral leishmaniasis (VL) caused by Leishmania infantum received liposomal amphotericin B (AmBisome) in a multi-centre study. Ten immunocompetent patients (six children) received 1-1.38 mg/kg/day for 21 days, and ten (nine children) received 3 mg/kg/day for 10 days. All were cured without significant adverse events and without relapse during 12-24 months of follow-up. Eleven immunocompromised adults, including seven co-infected with HIV (four with AIDS) received 100 mg (1.38-1.85 mg/kg) daily for 21 days. All were initially considered cured, but eight relapsed clinically and parasitologically at 3-22 months. Liposomal amphotericin B is a new, safe and effective drug for the treatment of VL.
在一项多中心研究中，31例由婴儿利什曼原虫引起的内脏利什曼病（VL）患者接受了脂质体两性霉素B（安必素）治疗。10例免疫功能正常的患者（6名儿童）接受1-1.38毫克/千克/天的剂量，持续21天，另外10例（9名儿童）接受3毫克/千克/天的剂量，持续10天。所有患者均治愈，在12至24个月的随访期间无明显不良事件且无复发。11例免疫功能低下的成年人，包括7例合并感染HIV（4例患有艾滋病），接受每日100毫克（1.38-1.85毫克/千克）的剂量，持续21天。所有患者最初均被认为已治愈，但8例在3至22个月时出现临床和寄生虫学复发。脂质体两性霉素B是一种治疗VL的新型、安全且有效的药物。
